Hot Topics In Glomerulonephritis New Updates
- Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease
- Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
- Atrasentan in Patients with IgA Nephropathy
- Way Stations in Progress — Burgeoning Treatment Options for IgA Nephropathy
- Retrospective Analysis of the Outcomes of Mycophenolate Therapy in Retarding the Progression of Immunoglobulin A Nephropathy (REMISSION IgA)
- Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis
- The Intensity of Glomerular C3 Deposits in IgA Nephropathy Predicts Early Renal Replacement Therapy
- High Temperature Requirement Protein A1–Positive Membranous Nephropathy in a Patient With Chronic Lymphocytic Leukemia
- Non-Invasive Diagnostic Strategies for Membranous Nephropathy in the NEPTUNE Study
- Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy
- Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants
- Treatment of Nephrotic Syndrome With Antinephrin Antibodies Using Plasmapheresis, Rituximab, and Mycophenolate Mofetil
- Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy Andrew S. Bomback et.al. Kidney Int Rep (2025)
- Comparison of Obinutuzumab and Rituximab for Treating Primary Membranous Nephropathy Xiaofan Hu et.al. CJASN 2024
- Inebilizumab for Treatment of IgG4-Related Disease John H. Stone et.al. MITIGATE Trial NEJM 2024
- Spectrum of Alport syndrome in an Indian cohort Menka Yadav et.al. Pediatric Nephrology (2025)
- Why laser microdissection and mass spectrometry is the method of choice for detection of membranous nephropathy antigens Sanjeev Sethi et.al. Clinical Kidney Journal,2024
- Statin Induced Proteinuria: Renal Injury or Renoprotection? RAJIV AGARWAL JASN 2004
- Primary IgA Nephropathy: New Insights and Emerging Therapies Haresh Selvaskandan et.al.
- IgA nephropathy Stamellou et al. Nat Rev Dis Primers 2023
- Differential long-term impact of primary glomerular diseases on major outcomes: All are not equal! A G Stack et.al. The Association for the Publication of the Journal of Internal Medicine 2025
- Complement Inhibitors for the Treatment of C3G: The Dawn of a New Era Kirsten Martin et.al. ASN Kidney News 2025
- Autoantibodies in the Pathogenesis of Podocytopathies Lukas Blume et.al. JASN 2025
- Ef cacy and Safety of Subcutaneous Rituximab in Idiopathic NephroticSyndrome, Paolo Cravedi et.al. ; KI Reports 2024.
- Atrasentan in Patients with IgA Nephropathy, Hiddo J.L. Heerspink et.al. ; NEJM 2024.
- Membranous nephropathy treatment standard, Yeshwanter Radhakrishnan et.al.; NDT 2024.
- Different Dosage Regimens of Rituximab in Primary Membranous Nephropathy Treatment: A Systematic Review, Yi Yu et.al. ; International Journal of Nephrology and Renovascular Disease 2024.
- Effects of immunosuppressive therapyon renal prognosis in primary membranous nephropathy, Wangyang Li et.al. ; BMC Nephrology 2024.
- C3G and Ig-MPGN—treatment standard, Marina Noris et.al. ; NDT 2024.
- Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membrano proliferative Glomerulonephritis
-
Validation of 2 Prognostic Models to PredictRenal Allograft Outcome After IgANephropathy Recurrence
-
Tacrolimus or Mycophenolate Mofetil for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome
- Questions and Caveats in Antigen-Defined Membranous Nephropathy
- Diagnostic Immunostaining of Renal Biopsies: An Overview of Markers for Glomerular Diseases
- Methods for Diagnosing Proteinuria—When to Use Which Test and Why: A Review
- Non-invasive Diagnosis of Antinephrin–AssociatedPodocytopathy
- Decoding Glomerular Disease: Baseline Profiles and Insights From the I-TANGIBLE Registry
-
Podocyte-targeted therapies — progress and future directions
- Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials
- Malignancies and glomerulonephritis: when to suspect and when to screen?
- IgG4-Related Kidney Disease
-
A Renaissance of Clinical Trials for IgA Nephropathy—Can the Same Occur for Membranous Nephropathy?
- Treatment of patients with IgA nephropathy:a call for a new paradigm
- Prophylactic and Therapeutic Anticoagulation in Nephrotic Syndrome Using Direct Acting Oral Anticoagulants
- Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
- High Temperature Requirement Protein A1–Positive Membranous Nephropathy in a Patient With Chronic Lymphocytic Leukemia
- Treatment of Nephrotic Syndrome With Antinephrin Antibodies Using Plasmapheresis, Rituximab, and Mycophenolate Mofetil
- Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease
- Recent advances in pathogenetic concepts and diseasemodeling of IgA nephropathy
- Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies
-
The pathogenesis of IgA nephropathy and implications for treatment
-
When Serum Anti–Phospholipase A2 Receptor Antibodies Go Missing: The Challenge of Predicting Relapse